Mega-Trials: the new norm?

Numerous pharmaceuticals are approved and marketed based on the premise that they favorably change disease state-biomarkers. However, recent data has shown that altering the biomarkers indicative of disease does not necessarily translate to ameliorated health.  In an...

Advances in Mobile Technology Transform Clinical Trials

A recent article from mobihealthnews.com describes how technology is helping streamline clinical trials by bridging communication between investigators, pharmaceutical companies and participants. Communication between companies and third party investigators is often a...

NCI receives enthusiastic feedback from recent pilot study

Huron Life Sciences recently released an article about a recent pilot study conducted by National Cancer Institute (NCI). During the month of October, The NCI conducted a pilot study testing feasibility of using an independent CIRB model. Twenty- four institutions...